Poor
Not Aligned
Patient Risk:
Moderate
Summary
Some core immunization warnings are supported (avoid live vaccines; may alter immune response to live vaccines), but many additional claims are unsupported or conflict with the provided label excerpts, especially the repeated 4-week/2-week timing guidance and multiple external guideline/study assertions.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A).
Supported by 12.1 Clinical Pharmacology (Mechanism of Action).
Cosentyx may lead to a reduced response to live vaccines.
Supported by 5.7 Immunizations: "COSENTYX may alter a patient's immune response to live vaccines."
Cosentyx may interfere with the body's ability to mount an effective immune response to live vaccines.
Supported by 5.7 Immunizations: "may alter a patient's immune response to live vaccines."
It is generally recommended to avoid live vaccines while taking Cosentyx.
Supported by 5.7 Immunizations: "Avoid use of live vaccines in patients treated with COSENTYX."
While on Cosentyx, patients should be monitored for signs of infection (contact clinician if symptoms occur).
Supported generally by 17 Patient Counseling Information: instruct patients to contact their doctor if they develop symptoms of infection.
Unsupported Statements
Cosentyx reduces inflammation and slows disease progression in psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Provided label evidence does not include Indications and Usage text, nor any supporting disease-progression wording in the available sections.
If the immune system is weakened, patients on Cosentyx may be more susceptible to infections from live vaccines.
The provided label excerpts do not state that susceptibility to infections specifically attributable to live vaccines is increased.
The decision to administer live vaccines to patients on Cosentyx should be made on a case-by-case basis, taking into account the individual's medical history and the specific vaccine being administered.
The provided label excerpts instruct to avoid use of live vaccines in patients treated with COSENTYX; no case-by-case permission framework is provided.
While there is limited data on the safety of live vaccines on Cosentyx, patients should be monitored closely for any signs of infection or adverse reactions.
The provided label excerpts do not mention "limited data" specific to live vaccines safety.
The CDC recommends that patients on Cosentyx receive live vaccines at least 4 weeks before starting treatment or 4 weeks after discontinuing treatment.
No CDC recommendation or timing interval appears in the provided label excerpts.
The American Academy of Dermatology suggests that patients on Cosentyx receive live vaccines at least 2 weeks before starting treatment or 2 weeks after discontinuing treatment.
No AAD recommendation or timing interval appears in the provided label excerpts.
A study in the Journal of the American Academy of Dermatology found that patients on Cosentyx who received the MMR vaccine experienced a similar immune response to those who did not receive the vaccine.
No such journal study details are present in the provided label excerpts.
A study in the Journal of Rheumatology found that patients on Cosentyx who received the oral poliovirus vaccine experienced a reduced immune response compared to those who did not receive the vaccine.
No such journal study details are present in the provided label excerpts.
Live vaccines should be administered at least 4 weeks before starting Cosentyx or 4 weeks after discontinuing treatment.
The provided label excerpt (5.7 Immunizations) instructs to avoid live vaccines and does not provide a 4-week timing instruction.
Patients on Cosentyx should be closely monitored for any signs of infection or adverse reactions after receiving live vaccines.
The provided label excerpts support infection-related monitoring generally, but do not specifically instruct monitoring "after receiving live vaccines" or link monitoring to live-vaccine administration.
The CDC recommends waiting at least 4 weeks before receiving live vaccines after starting Cosentyx.
No CDC timing interval appears in the provided label excerpts.
The risks of receiving live vaccines on Cosentyx include a weakened immune response, increased risk of infection, and interference with vaccine efficacy.
The provided excerpts support possible alteration of immune response to live vaccines, but do not support the full combined triad/wording including "interference with vaccine efficacy" and a specific increased infection risk from live vaccines.
Live vaccines can be received after discontinuing Cosentyx if at least 4 weeks are waited before receiving live vaccines.
No post-discontinuation timing instruction appears in the provided label excerpts.
Contradictions
Low
AI Statement
Live vaccines should be administered at least 4 weeks before starting Cosentyx or 4 weeks after discontinuing treatment.
Label Reference
5.7 Immunizations ("Avoid use of live vaccines in patients treated with COSENTYX").
Low
AI Statement
The decision to administer live vaccines to patients on Cosentyx should be made on a case-by-case basis, taking into account the individual's medical history and the specific vaccine being administered.
Label Reference
5.7 Immunizations ("Avoid use of live vaccines in patients treated with COSENTYX").
Important Omissions
Boxed warnings, contraindications, dosage/administration details, and specific population guidance were not evaluated because the provided label excerpts do not include those sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported and potentially conflicting timing/case-by-case vaccine administration guidance (e.g., 4-week/2-week intervals; permitting live vaccines) is a material mismatch with the provided label instruction to avoid live vaccines in patients treated with COSENTYX.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims about external recommendations and specific 2-week/4-week timing and live-vaccine eligibility are not supported by the provided label excerpts and conflict with the provided instruction to avoid live vaccines during treatment.
Suggested Improvement
Limit live-vaccine statements to what is supported by 5.7 Immunizations and 17 Patient Counseling Information (i.e., avoid live vaccines in patients treated with COSENTYX; COSENTYX may alter immune response to live vaccines; contact clinician if infection symptoms occur). Remove or qualify unsupported external guideline and study-specific timing/immune-response claims unless corresponding label text is provided.